By Debra Michaels, Associate Director, Scientific Programs, Americas, DIA
Biopharmaceutical development and the broader healthcare industry are faced with growing challenges. The rising cost of healthcare is not sustainable, and the development of biopharmaceutical therapies is too expensive and too slow. Can new technologies such as artificial intelligence (AI), machine learning (ML), “bots,” and other digital tools, help accelerate the pace of development and approval of new therapies? At DIA Europe 2019, a diverse panel looked at the potential impact of new technologies and necessary steps to leverage them.